Medscape February 3, 2025
The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 announcement from its manufacturer, Celltrion.
Avtozma, an anti-interleukin 6 receptor antagonist, is approved for all of the same indications as reference tocilizumab (Actemra) — rheumatoid arthritis (RA), giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and coronavirus disease (COVID-19) — except for systemic sclerosis-associated interstitial lung disease.
The biologic is the third FDA-approved biosimilar of Actemra and will be available in both intravenous (IV) and subcutaneous (SC) formulations at the same dosages as Actemra. The dosage options for the IV formulation are 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20...
Today's Sponsors
Today's Sponsor